Search

Displaying results 3311 - 3320 of 5449 in total
  1. Drug

    Streptococcus pneumoniae type 19f capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10336
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

  2. Drug

    Streptococcus pneumoniae type 33f capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10341
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

  3. Drug

    Efinaconazole

    go.drugbank.com/drugs/DB09040
    ApprovedInvestigational

    It was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia.

  4. Drug

    Rubella virus vaccine

    go.drugbank.com/drugs/DB10317
    ApprovedInvestigational

    It is prepared from RA 27/3 strain of live attenuated rubella virus. Rubella is a common childhood disease, caused by rubella virus (togavirus).

  5. Drug

    19-Nor-5-androstenedione

    go.drugbank.com/drugs/DB01443
    ExperimentalIllicit

    It is regulated in the United States as a schedule III controlled substance, and prohibited by the World Anti-Doping Agency for use in competitive sports.

  6. Drug

    Abatacept

    go.drugbank.com/drugs/DB01281
    ApprovedInvestigational

    It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. … Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human

    Categories: Selective T Cell Costimulation ModulatorProducts: ORENCIA 250 MG KON.PERFUZYONLUK COZ.ICIN TOZ ICEREN FLAKON, ORENCIA® SOLUCION INYECTABLE PARA ADMINISTRACION SUBCUTÁNEA 125 MG/ML
  7. Drug

    Calcium threonate

    go.drugbank.com/drugs/DB11168
    ApprovedWithdrawn

    It is found in dietary supplements as a source of L-threonate used in the treatment of calcium deficiency and prevention of osteoporosis. … Therapeutic efficacy of calcium threonate in reducing was studied and investigated due to the hypothesis that it may play a role in the mineralization process through its positive action on vitamin C.

  8. Drug

    Zilganersen

    go.drugbank.com/drugs/DB18161
    ApprovedInvestigational

    [L64096] It is administered by intrathecal injection, and requires dilution with an accompanying artificial cerebrospinal fluid diluent before administration. … [L64096] The FDA approved zilganersen on September 3, 2026 for the treatment of Alexander disease in pediatric and adult patients, making it the first and only disease-modifying treatment for the condition

  9. Drug

    Pegulicianine

    go.drugbank.com/drugs/DB18731
    ApprovedInvestigational

    [L50537,L50547] It received Fast Track and priority review for this indication.[L50547] … It is used following surgical resection of the primary tumor to detect areas of remaining cancer.

  10. Drug

    PA-1050040

    go.drugbank.com/drugs/DB06039
    Experimental

    It inhibits virus replication by the same mechanism of action as BVM.